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Abstract The CDH1 gene plays an important role during
carcinogenesis and craniofacial morphogenesis. Germline
mutations in this gene have been described in families
presenting syndromic diffuse gastric cancer and orofacial
clefts. The aim of this study was to evaluate the association
between nucleotide variants of CDH1 and the risk of non-
syndromic cleft lip with or without cleft palate (NSCL/P).
Six single nucleotide polymorphisms (SNPs) of the CDH1
gene (rs16260, rs9929218, rs7186053, rs4783573,
rs16958383, and rs1801552) were genotyped using the
TaqMan SNP genotyping assays in 250 patients with
NSCL/P and 540 controls from the Polish population.
Comparison between patient and control groups showed
that the CDH1 rs1801552 variant, under the assumption of
recessive model, was associated with a two-fold decrease
in the risk of NSCL/P (ORTT vs CT ? CC = 0.481, 95 % CI
0.281–0.824, p = 0.007). This association remained sta-
tistically significant even after the multiple testing correc-
tion. No significant associations with NSCL/P risk were
found for the other five tested SNPs. We found a strong
association between the cancer predisposing gene CDH1
and the risk of NSCL/P in the Polish population. This
result, together with previous observations of co-occur-
rence of orofacial clefts and a variety of cancer types,
suggests the need for replication studies testing rs1801552
in NSCL/P cohorts with a known cancer history.
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Introduction
Non-syndromic cleft lip with or without cleft palate
(NSCL/P, OMIM 119530) is the most common facial birth
defect and can cause problems with feeding, hearing,
speaking, emotional development and social integration
during growth [1]. Orofacial clefts have a complex etiology
with both genetic and environmental factors contributing to
the condition [1, 2]. Well known candidate genes, which
are correlated with the risk of NSCL/P in various popula-
tions, include IRF6, VAX1 and the 8q24 locus [1, 3].
However, their nucleotide variants do not account for all
observed NSCL/P cases, emphasizing the need for identi-
fying new genetic factors associated with NSCL/P.
Several studies have reported an association between
orofacial clefts and cancer [4–6]. It has been proposed that
these disorders may occasionally have a common etiology
[4, 6]. Factors that have been suspected to be at the basis of
these associations are polymorphic variants in genes
involved in cell-to-cell adhesion and cell motility [4, 6].
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Gastric cancer is the fourth most common malignancy and
the second leading cause of death due to cancer worldwide
[7]. The vast majority of gastric cancers are sporadic,
although a small number, 3–5 % of them, is caused by an
autosomal dominant inherited trait. The majority of fami-
lies with autosomal dominant gastric carcinoma have the
diffuse, poorly differentiated morphologic subtype (linitis
plastica) which is referred to as hereditary diffuse gastric
cancer (HDGC) [8, 9]. There is also emerging evidence for
an increased risk of lobular breast cancer and colon cancer
in HDGC families [8, 9]. Approximately 25–48 % of the
individuals with HDGC have an autosomal dominant
inherited germline CDH1 mutation or large deletion
affecting the CDH1 locus. The CDH1 gene, located on
chromosome 16q22.1, encodes E-cadherin (OMIM:
*192090), which is involved in epithelial calcium-depen-
dent cell-to-cell adhesion [10, 11]. Currently, there are no
reliable clinical screening methods for early detection of
HDGC, which is located submucosally. Prophylactic total
gastrectomy is the recommended form of management for
individuals over 20 years of age carrying a CDH1 muta-
tion, because of their 80 % lifetime risk of developing
gastric cancer and the limited value of surveillance
modalities [8, 9]. The increased occurrence of cleft lip/cleft
palate in HDGC patients with a CDH1 mutation was sug-
gested by Frebourg et al. [12] and supported by Kluijt et al.
[13], who have described 4/58 (7 %) CDH1 germline
mutation carriers with orofacial cleft in the Dutch study for
familial cancer. In France, approximately 6 % of registered
CDH1 germline mutation carriers have an orofacial cleft
[14]. Recently, the incorporation of a family history of
orofacial cleft was suggested into the new HDGC-defining
criteria [14].
The most widely studied polymorphic variant of the
CDH1 gene is rs16260 (-160C[A), located upstream of
the transcriptional start site of the CDH1 promoter [11].
It has been shown that the -160A allele decreases the
transcription efficiency of the CDH1 gene [15, 16]. Meta-
analyses suggest that rs16260 may be associated with the
risk of colorectal cancer (CRC) in Western populations and
sporadic gastric carcinoma among Caucasians, but not
among Asians [11, 17]. Interestingly, in the study of Zhan
et al. [18], genotypes of the CDH1 rs16260 variant con-
tributed to the risk of diffuse gastric cancer in ethnic Han
Chinese. In the same population, Song and Zhang [19]
found no significant association between NSCL/P and
rs16260, whereas an association was observed for isolated
cleft palate. The study of Rafighdoost et al. [20] revealed
significant impact of the rs16260 AC and AA genotypes on
NSCL/P risk in Iranians. Furthermore, two functionally
missense germline mutations of CDH1 were recently
identified in 5.2 % (3/58) of children of European descent
with NSCL/P [21]; however, there are unfortunately no
studies assessing the association between rs16260 and
NSCL/P in Europeans. Identification of clinical and
molecular markers of individuals at increased risk of
developing sporadic and familial gastric cancer are needed.
There is strong evidence showing a positive association
between the mislocalized, diminished or absent E-cadherin
immunoreactivity and gastric cancer, and therefore,
whenever possible, it is important to define the pathoge-
nicity, as well as phenotypic manifestations, of CDH1
variants [8, 14, 18]. Individuals identified as carrying
specific genetic variants can be the target of more aggres-
sive screening programs [4]. Development of early
screening protocols for patients with orofacial clefts may
lead to early stage diagnoses of cancer.
Therefore, we conducted an association study to deter-
mine whether common nucleotide variations in the CDH1
gene may contribute to the risk of NSCL/P in the Polish
population.
Materials and methods
Patients and controls
Peripheral blood samples from 250 unrelated subjects with
NSCL/P were obtained from the Department of Paediatrics
and Paediatric Surgery at the Institute of Mother and Child
in Warsaw, the Department of Plastic Surgery Specialist
Medical Center in Polanica Zdroj, and from the Depart-
ment of Jaw Orthopaedics at the Medical University of
Lublin. Eligibility to the patient group was ascertained
from detailed medical records. Patients (aged 1–15 years)
were examined by experienced medical geneticists. The
non-syndromic designation was based on diagnosis of
isolated CL/P with no other apparent cognitive and struc-
tural anomalies. Individuals with cleft palate only (CPO)
were excluded from the study. The control group was
composed of 540 healthy individuals with no family his-
tory of cleft lip and palate or other congenital anomalies.
All participants were Caucasians of Polish origin born in
Poland. DNA was isolated from peripheral blood lym-
phocytes by a salting-out extraction procedure. The
experiments were approved by the local Ethics Committee
at the Poznan University of Medical Sciences. Written and
oral consent was obtained from the legal guardians of all
the participants.
SNP selection and genotyping
Single nucleotide polymorphisms (SNPs) in CDH1 were
identified from public databases including the NCBI
dbSNP database (http://www.ncbi.nlm.nih.gov/projects/
SNP/) and the HapMap Genome Browser (http://hapmap.
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ncbi.nlm.nih.gov/), and related literature. A final set of 6
SNPs was selected based on minor allele frequency (MAF)
over 15 % in the Caucasian population, the gene-linkage
disequilibrium (LD) patterns, and functional significance of
SNPs. The LD pattern and the structure of haplotype blocks
across the CDH1 gene were determined using genotype
data from the HapMap database and Haploview 4.0 soft-
ware package (http://www.broad.mit.edu/mpg/haploview/).
The plot of the pairwise LD between SNPs in CDH1 is
presented in Fig. 1. Characteristics of SNPs selected for the
final analysis are presented in Table 1. Genotyping was
carried out on the LightCycler 480 system (Roche Diag-
nostics, Mannheim, Germany) using pre-designed and
custom TaqMan SNP Genotyping Assays according to the
manufacturer’s instructions provided by Applied Biosys-
tems (Applied Biosystems, Foster City, CA). Data analysis
was performed using the Endpoint Analysis module of
LightCycler 480 Software 1.5. For quality control, the
genotyping analysis was blinded to the subject’s case–
control status. In addition, approximately 10 % of the
randomly chosen samples were re-genotyped.
Statistical analysis
For each SNP, the Chi square test (v2) for Hardy–Weinberg
equilibrium (HWE) and minor allele frequency (MAF)
were computed among both NSCL/P patients and controls.
The differences in allele and genotype frequencies between
patients and controls were determined using standard v2
and Fisher exact tests. SNPs were tested for association
with NSCL/P using the Cochran-Armitage trend test. Odds
Ratios (ORs) with 95 % Confidence Intervals (95 % CIs)
Fig. 1 The linkage disequilibrium (LD) plot of HapMap SNPs within
the CDH1 region. The plot was generated using the genotype data
from HapMap CEU samples and the Haploview 4.0 software (Broad
Institute, Cambridge, MA). The names of the examined SNPs are
enclosed in boxes. The numbers in the squares indicate percentage of
LD between a given pair of SNPs (D’ values). Blue squares are non-
informative. (Color figure online)
Table 1 Characteristics of the CDH1 polymorphisms genotyped in the dataset
rs no. Chromosomal positiona SNP function Allelesb MAFc
rs16260 chr16:68771034 nearGene-5 A/C (FWD) 0.29
rs9929218 chr16:68820946 intron A/G (FWD) 0.29
rs7186053 chr16:68839293 intron A/G (FWD) 0.45
rs4783573 chr16:68840588 intron A/G (FWD) 0.27
rs16958383 chr16:68857000 intron A/G (FWD) 0.19
rs1801552 chr16:68857441 cds-synon (Ala692Ala) C/T (FWD) 0.36
FWD forward, REV revers
a Accordnig to the February 2009 human reference sequence (GRCh37)
b According to the single nucleotide polymorphism database (dbSNP); Underline denotes the minor allele in the control samples
c MAF minor allele frequency calculated from the control samples
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were used to assessed the strength of the association. The
dominant and recessive models were analyzed. A statistical
adjustment for multiple comparisons was accomplished by
using the Bonferroni correction. Statistical significance was
interpreted as p values \0.00833. Pair-wise LD was
calculated as both D’ and r2 for all tested SNPs using
Haploview software. Haplotype association testing was
performed using the UNPHASED 3.1.5 program with the
following analysis options: all window sizes, full model
and uncertain haplotype option [22]. Statistical significance
was assessed using the 1,000-fold permutation testing.
Results
Single-marker association analysis
All tested SNPs did not show deviation from HWE in both
patients and controls (p [ 0.05). The MAF for tested
markers was at least 19 %. The genotyping results, OR and
95 % CI calculations for the 6 tested SNPs of CDH1 are
reported in Table 2. Under assumption of a recessive
model (TT vs CC ? CT, where T is the minor allele),
the calculated OR for rs1801552 was 0.481 (95 % CI
0.281–0.824, p = 0.0016). This result was statistically
significant even after Bonferroni correction (p \ 0.00833).
The OR calculated for individuals with the combined TT
and CT genotypes of the rs1801552 polymorphism com-
pared to CC homozygotes (dominant model) was 0.955
(95 % CI 0.705–1.293), but the result was not statistically
significant (p = 0.764). For rs1801552, the genotype fre-
quencies showed a significant difference between cases and
controls (p = 0.021). For the remaining analyzed CDH1
SNPs, there was no evidence for both allelic and genotypic
association with the risk of orofacial clefts (Table 2).
Analysis of pair-wise LD between the investigated CDH1
SNPs revealed that rs1801552 was not correlated with
other variants. D’ and r2 values, calculated from the
genotype data of the control samples, ranged from 0.033 to
1.000 and 0.001 to 0.129, respectively (Table 3).
Haplotype analysis
Haplotype analysis of the studied CDH1 polymorphisms
did not show SNP combinations associated with the risk of
NSCL/P (Table 4). The lowest global p = 0.087 was
observed for haplotype composed of the rs9929218,
rs7186053, rs4783573 and rs16958383 SNPs (Table 4).
However, this result was not statistically significant when
permutations were used to generate empiric p-values.
The empirical 5 % quintile of the best p value after 1,000
permutations was 0.003295.
Discussion
Abnormal CDH1 expression has been linked to many
human diseases, including tumors, nephrolithiasis, pre-
eclampsia, and ectopic pregnancy [10, 11]. Although great
advances have been achieved in gene identification for
Table 2 Association of polymorphic variants of CDH1 with the risk of NSCL/P
rs no. Allelesa MAFb Genotypes
casesc
Genotypes
controlsc
ptrend
value
pgenotypic
value
pallelic
value
ORdominant
(95 % CI)d; p value
ORrecessive
(95 % CI)e; p value
rs16260 A/C 0.29 22/97/131 49/213/278 0.811 0.970 0.807 0.964 (0.714–1.301);
0.810
0.967 (0.571–1.638);
0.900
rs9929218 A/G 0.29 22/102/126 48/222/270 0.921 0.995 0.921 0.984 (0.729–1.328);
0.917
0.989 (0.583–1.678);
0.967
rs7186053 A/G 0.45 48/118/84 111/261/
168
0.480 0.766 0.474 0.893 (0.648–1.229);
0.485
0.918 (0.630–1.340);
0.659
rs4783573 A/G 0.27 18/95/137 40/210/290 0.787 0.959 0.785 0.957 (0.708–1.293);
0.774
0.970 (0.544–1.728);
0.917
rs16958383 A/G 0.19 8/78/164 23/155/362 0.930 0.637 0.929 1.066 (0.777–1.464);
0.690
0.743 (0.328–1.686);
0.476
rs1801552 C/T 0.36 18/125/107 75/240/225 0.126 0.021 0.129 0.955 (0.705–1.293);
0.764
0.481 (0.281–0.824);
0.007
Statistically significant results are highlighted in bold (p \ 0.00833—Bonferroni correction)
a Underline denotes the minor allele in the control samples
b MAF minor allele frequency calculated from the control samples
c The order of genotypes: dd/Dd/DD (d is the minor allele in the control samples)
d Dominant model: dd ? Dd versus DD (d is the minor allele)
e Recessive model: dd versus Dd ? DD (d is the minor allele)
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NSCL/P, the underlying molecular mechanisms remain
obscure. Identifying the underlying etiology is crucial in
improving prevention strategies and genetic risk counsel-
ing. Recent epidemiological findings point toward at least
some shared genetic risk factors of NSCL/P and cancer [4,
5]. It is possible that several truly NSCL/P associated
variations are hidden among the list of moderately signif-
icant SNPs. In this study, we assessed if polymorphic
variants in the cancer predisposing gene CDH1 are asso-
ciated with NSCL/P in a sample from the Polish popula-
tion. Our results suggest that the presence of the CDH1
rs1801552 TT genotype is associated with a two-fold
decreased risk for NSCL/P in the investigated population,
but further studies with larger cohorts from different pop-
ulations and taking into account family history of cancer
are warranted. Unfortunately, there are no published
association studies of rs1801552 and gastric cancer in
Poland. In China, this polymorphic variant of CDH1 has
not achieved significant difference in its distribution
between gastric cancer cases and controls [18]. The Ger-
man study of Jacobs et al. [23] revealed a contribution of
CDH1 rs1801026, but not rs1801552, to a predisposition to
the development of primary gastric diffuse large B-cell
carcinoma. The impact of the rs1801552 polymorphism on
CDH1 activity in tissues remains unclear. However, a
significant difference in plasma CDH1 levels among car-
riers with different CDH1 rs1801552 genotypes has not
been reported [18]. Further in vitro and in vivo functional
studies are needed to characterize the functional signifi-
cance of this SNP. Loss of expression of E-cadherin leads
to an increased ability of cells to invade neighboring tissues
[10, 16]. Our findings are of interest especially in light of
observations showing that individuals without a CDH1
mutation that are presenting with tumors that have E-cad-
herin expression impairment, similar to that observed in
CDH1 germline mutation carriers with HDGC, may have a
CDH1 expression defect caused be either direct or indirect
mechanisms targeting the CDH1 genomic sequence [24].
In respect to this assumption, the reported simultaneous
familial occurrence of NSCL/P and cancer could provide
clues to consider CDH1 rs1801552 as a potential marker of
cancer susceptibility [4, 6].
Our study has not confirmed an association between
rs16260 and NSCL/P, which is controversial [19, 20]. Our
single-marker analyses also did not show any evidence of
correlation between the remaining rs9929218, rs7186053,
Table 3 Linkage
disequilibrium between markers
of the CDH1 gene in the control
samples
D0 above diagonal
r2 below diagonal
rs16260 rs9929218 rs7186053 rs4783573 rs16958383 rs1801552
rs16260 0.982 0.909 0.851 0.829 0.131
rs9929218 0.934 0.890 0.831 0.834 0.139
rs7186053 0.413 0.409 0.734 0.541 0.112
rs4783573 0.108 0.106 0.16 0.322 0.033
rs16958383 0.064 0.066 0.054 0.065 1.000
rs1801552 0.012 0.014 0.006 0.001 0.129
Table 4 Results of haplotype
analysis of the CDH1 gene in
patients with NSCL/P
Empirical 5 % quantile of the
best p value: 0.003295
Polymorphisms V2 Global p value
rs16260_rs9929218 4.736 0.192
rs9929218_rs7186053 0.439 0.508
rs7186053_rs4783573 2.230 0.135
rs4783573_rs16958383 0.239 0.971
rs16958383_rs1801552 2.537 0.281
rs16260_rs9929218_rs7186053 2.156 0.541
rs9929218_rs7186053_rs4783573 4.654 0.199
rs7186053_rs4783573_rs16958383 6.507 0.089
rs4783573_rs16958383_rs1801552 5.674 0.339
rs16260_rs9929218_rs7186053_rs4783573 8.512 0.290
rs9929218_rs7186053_rs4783573_rs16958383 11.060 0.087
rs7186053_rs4783573_rs16958383_rs1801552 8.309 0.306
rs16260_rs9929218_rs7186053_rs4783573_rs16958383 15.298 0.122
rs9929218_rs7186053_rs4783573_rs16958383_rs1801552 13.329 0.272
rs16260_rs9929218_rs7186053_rs4783573_rs16958383_rs1801552 18.936 0.272
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rs4783573, and rs16958383 CDH1 variants and the risk of
NSCL/P. The last two SNPs were previously tested as
breast cancer susceptibility markers in China [25]. The
CDH1 rs16958383 has been found to have a borderline
association with breast cancer in premenopausal, but not
postmenopausal, women [25]. Recently, Ierodiakonou et al.
[26] showed that rs7186053, rs4783573 and rs16958383
may contribute to airway remodeling and lung function
in asthma patients using inhaled corticosteroids, however
their impact on pulmonary cancer has yet to be elucidated.
Haplotype analysis has shown that the 4-SNP haplotype
composed of rs9929218, rs7186053, rs4783573 and
rs16958383 tends to be correlated with the risk of NSCL/P
in our study population. Previously, rs9929218 was shown
to have a borderline association with unilateral NSCL/P in
Brazilians, who have undergone varying degrees of
admixture with ancestors from widely divergent regions
[27]. Taken together, the findings suggest this nucleotide
variant may have different associations with NSCL/P
etiology depending on specific ancestry. Evaluations of
rs9929218 in relation to CRC risk and survival also showed
significant associations [28, 29]. Thus, further examination
of haplotypes in CDH1, including rs9929218, is needed to
identify a biologically relevant cause.
Compaction of the preimplantation embryo is consid-
ered the earliest morphogenetic process essential for
mammalian development. E-cadherin dependent filopodia
attaching onto neighboring cells were demonstrated to
control the shape changes necessary for compaction [30].
Leitra et al. [27] and Rafighdoost et al. [20] have suggested
that CDH1 may be a very reasonable candidate gene for
NSCL/P. In mammals, CDH1 is required during early
development and in establishing a proper connection
between embryonic and maternal blood vessels [10]. It is
expressed in the epithelium of the palate prior to and after
shelf fusion. Epithelial to mesenchymal transition (EMT) is
regarded an integral process in palatogenesis [27]. b-cate-
nin, a member of the protein complex connecting cadherins
to the actin cytoskeleton at adherens junctions, plays a
crucial role in the onset and progression of EMT. At an
early stage of transformation, the epithelial cell down-
regulates its expression of E-cadherin, which frees the
attachment of the cells from one another [10, 16]. It has
been demonstrated that E-cadherin can compete with the
transcriptional activity of the canonical WNT signaling
pathway, increasing cell proliferation [31]. Interestingly, in
our previous study we showed that a polymorphic variant
of the gene encoding WNT3 and haplotype combinations
of the WNT3 SNPs were significantly correlated with the
NSCL/P in the Polish population [32].
Although open to question, nutrients and nutrient-related
transport factors have also been suggested as influential in
orofacial cleft risk [1]. Cdh1 was shown to be involved in
the mammalian endocycle, also known as endoreplicative
cycle, and to participate in the differentiation of trophoblast
stem cells to trophoblast giant cells during placental
development [33].
The major limitations of this study are the sample size,
which did not allow us to detect modest associations and
interactions, and lack of data regarding personal and
familial cancer history of participants. It would be inter-
esting to explore the presented correlations in relation to
cancer history. We must also note that the number of
selected polymorphisms does not cover the CDH1 gene
fully and extensively. Allele frequencies are known to vary
among different populations and different ethnic back-
grounds. However, our study population was ethnically
homogenous.
In summary, in this study we successfully genotyped six
SNPs of CDH1 in patients with NSCL/P and a properly
matched control group. After adjusting for multiple com-
parisons, the CDH1 rs1801552 variant was found to be
associated with a protective effect against the risk of
NSCL/P in the Polish population. Our results suggest the
need for replication studies using the identified SNP
associated with orofacial cleft susceptibility in NSCL/P
cohorts with known cancer history in the participants and
their families. If the nucleotide variant is again found to be
associated with NSCL/P in a second population, then
functional studies should be designed in an attempt to
determine its biological role.
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